You are here: Home » Companies » Financial X-Ray
RailTel's Rs 820-cr IPO subscribed 2.6 times on Day-1; Nureca by 15x
Business Standard

Asset monetisation, sales uptick in US key triggers for Glenmark Pharma

The India business is expected to post double digit growth in FY22

Topics
Glenmark Pharmaceuticals | Pharma industry | Pharmaceutical companies

Ram Prasad Sahu  |  Mumbai 



Glenmark Pharmaceuticals
The company, which has a net debt of Rs 3,614 crore at the end of the December quarter expects a reduction of Rs 200-300 crore in FY21 and a higher proportion in FY22.

Revenue growth reported by Glenmark Pharma in the December quarter was entirely due to the Indian operations and higher active pharmaceutical ingredient (API) sales.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Tue, February 16 2021. 18:43 IST

RECOMMENDED FOR YOU

.